Medpace (NASDAQ:MEDP) Price Target Cut to $539.00 by Analysts at Truist Financial

Medpace (NASDAQ:MEDP) had its price objective reduced by Truist Financial from $555.00 to $539.00 in a report issued on Wednesday, Marketbeat.com reports. They currently have a hold rating on the stock.

MEDP has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. BMO Capital Markets initiated coverage on shares of Medpace in a research report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price target for the company. Barclays boosted their price target on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. Finally, Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $477.36.

Medpace Trading Down 5.0%

MEDP opened at $423.93 on Wednesday. Medpace has a 1-year low of $250.05 and a 1-year high of $628.92. The firm has a 50-day moving average price of $572.49 and a two-hundred day moving average price of $538.75. The stock has a market capitalization of $11.94 billion, a PE ratio of 27.71, a PEG ratio of 1.45 and a beta of 1.42.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The business had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same quarter last year, the business posted $3.67 earnings per share. Medpace’s revenue for the quarter was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts predict that Medpace will post 12.29 EPS for the current year.

Insider Buying and Selling at Medpace

In other news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the transaction, the vice president owned 27,500 shares of the company’s stock, valued at $16,751,625. The trade was a 42.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO August J. Troendle sold 668 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $590.69, for a total value of $394,580.92. Following the sale, the chief executive officer directly owned 646,184 shares in the company, valued at $381,694,426.96. The trade was a 0.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 291,752 shares of company stock valued at $175,731,579. Corporate insiders own 20.30% of the company’s stock.

Institutional Investors Weigh In On Medpace

Large investors have recently modified their holdings of the business. Quent Capital LLC acquired a new position in shares of Medpace in the 3rd quarter valued at approximately $25,000. Optiver Holding B.V. acquired a new stake in Medpace during the 3rd quarter worth approximately $27,000. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Medpace in the fourth quarter valued at approximately $30,000. Finally, Elyxium Wealth LLC bought a new stake in shares of Medpace during the fourth quarter worth $30,000. 77.98% of the stock is currently owned by institutional investors.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.